Protocol BAY 59-7939: "An International, Mutlicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients with Symptomatic Peri

Project: Other project

StatusFinished
Effective start/end date2/15/161/26/17

Funding

  • Bayer Healthcare LLC: $6,153.85